Introduction
HIV infection and acquired immunodeficiency syndrome (AIDS) affect over 35 million people globally and new infections were estimated at over 2 million in 2014 [1] . The number of HIV-related deaths continues to decline, with 1.5 million people dying of AIDS-related causes in 2013, down 35% from the peak in 2005 [2] . The advent of antiretroviral therapy (ART) has improved morbidity and mortality to a point where HIV infection is now considered a treatable chronic disease [3] . The life expectancy among treated individuals is now comparable to that of the general population [4] . This extension in expected survival has resulted in the emergence of chronic diseases, including an increased incidence of coronary artery disease (CAD) [5] .
Mechanisms of coronary artery disease
Increased risk of CAD in patients with HIV infection has been associated with the inflammatory sequelae of the infection as well as the greater prevalence of cardiac risk factors in HIV-positive populations and the side effects of life-prolonging ARTs [6] [7] [8] . The underlying pathophysiological mechanisms resulting in the increased risk of CAD in patients with HIV infection are not well understood and probably are associated with a combination of traditional as well as novel risk factors (Fig. 1) . While the exact impact of cardiovascular disease in patients with HIV infection is still largely unknown -data remain inconsistent as a consequence of differences in populations, treatments and study designs -CAD has emerged as an important cause of mortality and morbidity in those living with HIV [9] .
Incidence of coronary disease in patients with HIV infection
Patients with HIV infection have a 1.5-to 2-fold greater risk of developing CAD compared with noninfected individuals, raising the independent risk of CAD in HIV infection to levels similar to those in individuals who smoke or have diabetes [7] . Those with HIV infection and symptomatic CAD present at a younger age and experience a higher rate of post-angioplasty restenosis [10] . Regarding subclinical disease, coronary artery plaques have been found to be more prevalent and extensive in HIV-infected men, although the significance of such findings remains unclear [11, 12] .
HIV infection and the implications of antiretroviral therapy on cardiac risk
The duration and use of specific antiretroviral drug regimens have been implicated as factors in explaining the risk of CAD and myocardial infarction in those with HIV infection [6, 8] . Protease inhibitors and some nucleoside reverse transcriptase inhibitors are generally thought to increase the risk of CAD development, but data have been conflicting [13, 14] . Several large studies have refuted the association between ART classes and CAD [15, 16] . In particular, the protease inhibitor ritonavir and more recently the nucleoside reverse transcriptase inhibitor abacavir have been implicated in conferring greater CAD risk on those with HIV infection [13, 14] , although a recent metaanalysis found no correlation between abacavir use and CAD risk [17] .
Despite efforts to disentangle which antiretroviral agents are responsible for the development of adverse lipid levels and CAD [18] , in clinical practice this delineation becomes difficult. ART is a combination of multiple agents from a variety of different classes that changes with advances in pharmacological research and individual patient circumstances. Therefore, at least from a pragmatic standpoint, considering these drugs as a whole entity is perhaps as useful as comparing individual drugs and classes. The lipid abnormalities generally seen in patients on ART are increased total cholesterol, with decreased high-density lipoprotein (HDL) cholesterol and hypertriglyceridaemia [19] . Hence, it is prudent to note that relying on absolute low-density lipoprotein (LDL) cholesterol levels in treated HIV-infected patients may underestimate their degree of cardiac risk because of concomitant lipid abnormalities.
Management of CAD risk factors in the HIV-infected population
Irrespective of the presence of established heart disease, first line intervention for all patients with HIV infection should include lifestyle modifications such as smoking cessation, regular exercise, weight loss and nutritional advice [20] . As with the general population, management of traditional risk factors with lifestyle modifications and medications is imperative to slowing the progression of CAD and improving clinical outcomes [21] . Given that patients with HIV infection have regular contact with health care professionals, there are frequent opportunities to provide counselling and intervention strategies.
Regarding weight, diet and exercise, adherence to the national guidelines is encouraged and should include a diet high in fruits, vegetables, lean meats and wholegrains along with the avoidance of foods high in sugar, saturated fat and salt. More than 30 min of moderate-intensity exercise each day is recommended along with the maintenance of a healthy weight and waist circumference [22] . For patients who smoke, both pharmacological and behavioural smoking cessation strategies should be considered [23] .
Diligent screening and management of diabetes and its complications are essential in HIV-positive populations. Current recommendations include a baseline fasting glucose and oral glucose tolerance test, with additional screening before and 3-6 months after the commencement of ART that includes a protease inhibitor. In those with identified impaired glucose metabolism, meticulous adherence to National Diabetes Management Guidelines is recommended. At minimum, this should include yearly (but preferably 3-6 monthly) retinal, foot and urinary albumin screening [24] . Where possible, metabolically favourable antiretroviral drug regimens should also be considered. If oral hypoglycaemic drug therapy is required, insulin-sensitizing agents such as metformin or thiazolidinediones are preferred [24, 25] .
Lipid-lowering recommendations should be based on the current guidelines for lifestyle interventions. An initial trial of 6 weeks of lifestyle modification is appropriate as per the guidelines, prior to the consideration of pharmacological intervention [22] . At first diagnosis, an initial baseline fasting lipid panel should be performed which includes total, LDL and HDL cholesterol and triglyceride levels [20, 25] .
Regarding the pharmacological management of lipid profiles, consideration needs to be given to the way in which lipid-lowering agents interact with ART. To varying degrees, most statins are metabolized in the liver by cytochrome P450 3A4, an enzymatic system that some antiretrovirals have been shown to down-regulate [20] . Protease inhibitors in particular have been implicated in the down-regulation of CYP34A and therefore, when used in conjunction with statin therapy, can lead to high serum concentrations and adverse side effects including hepatoxicity and myositis [20] .
Both atorvastatin and rosuvastatin are effective in reducing LDL cholesterol and triglyceride levels and neither is entirely metabolized by CYP34A, making them more likely to be safe to use in conjunction with protease inhibitors than other statins [20] . Despite this efficacy, studies assessing the safety of rosuvastatin when taken concomitantly with protease inhibitors are conflicting [26, 27] . Hence, as a consequence of its high efficacy and low interaction profile, currently atorvastatin is considered to be the first-line agent for hyperlipidaemia management in the HIV-infected patient [20] .
Assessing risk of CAD in the HIV-infected population
The ability to provide primary and secondary health interventions has led to the development and utilization of risk assessment tools to direct further investigations and management. These assessment tools use regression equations derived from a population sample of the Framingham heart and the Framingham offspring studies [28] . Although the Framingham risk calculators have been shown to predict risk reasonably well, the accuracy of these scores has been shown to vary across different population groups [29] [30] [31] . In patients with HIV infection, the Framingham risk score underestimates the presence of subclinical atherosclerosis, as well as under-predicting rates of myocardial infarction [32, 33] . These findings suggest that such tools are unhelpful in this population group where the CAD disease process is purportedly complicated by ART, chronic inflammation and oxidative stress on top of pre-existing conventional risk factors [33, 34] .
Consequently, HIV-specific risk assessment tools have emerged. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study was a prospective multinational cohort study that recruited 22 625 HIV-infected patients [35] . The study sought to develop a model that predicted the risk of CAD and its sequelae. The model includes age, sex, systolic blood pressure, smoking status, family history of CAD, diabetes, total cholesterol, HDL cholesterol and exposure to certain ART regimens. The DAD risk tool was found to be more accurate in predicting the risk of CAD and myocardial infarction compared with the traditional Framingham risk score in the HIV-infected population [35] .
Methods for screening CAD in the HIVinfected population
Despite almost half of all fatal myocardial infarctions occurring in previously asymptomatic patients [36] , controversy surrounds the role of screening and early management of CAD. Both the modality of screening and the timing of when to screen at-risk asymptomatic individuals remain unclear, even among the general population [37] . With the risk facing those with HIV infection thought to be similar to that of the diabetic population, where screening is appropriate, screening high-risk patients with treated HIV infection may be advantageous to improving outcomes [38] . However, to date no studies have shown a correlation between screening for CAD and an improvement in outcomes, so such suggestions are based on expert opinion rather than on evidence.
Regarding the modalities used to screen these high-risk patients, the cardiac investigations most commonly utilized include stress echocardiography, computed tomography coronary angiography (CTCA) and myocardial perfusion scanning [37] .
Stress echocardiography
The role of stress echocardiography in screening asymptomatic people in moderate-to high-risk populations is well documented, despite no specific data pertaining to those with HIV infection. Nevertheless, it appears reasonable to use stress echocardiography to screen for obstructive CAD in patients with HIV infection [38] . This modality, however, does not provide evidence on mild to moderate coronary disease [39] , which is available through CTCA [40] , suggesting that stress echocardiography should be used in those with optimal medical therapy, where the finding of early vascular disease will not change management (Fig. 2) . The finding of early atherosclerosis on CTCA enables clinicians to risk stratify and provide early intervention for their patients. CTCA allows insights into early plaque deposition where stress echocardiography only identifies patients with established vascular disease.
Myocardial perfusion scanning
The utility of myocardial perfusion scanning is uncertain as a result in part of its limited clinical availability. Moreover, the use of myocardial perfusion scanning as a first-line testing modality for risk stratification is currently not recommended in any category of primary prevention subjects [41] . Despite this, some guidelines have advocated the use of myocardial perfusion scanning in intermediate-risk or high-risk target populations [42] .
Computed tomography coronary angiography
CTCA allows an accurate assessment of the location and perfusion of atherosclerotic plaque in the coronary artery vasculature [43] . It can also gauge the degree of stenosis affecting a coronary vessel, determine if a plaque is obstructive or nonobstructive and provide calcium scoring as a surrogate measure of calcific CAD [40, 44] . Currently, 64-slice (or higher) CTCA is the noninvasive modality of choice for assessing CAD in a broad spectrum of patients [45] [46] [47] .
As a clinical tool it has a sensitivity of 98% and specificity of 88% and has been found to be as effective as standard invasive angiography in ruling out obstructive coronary disease [48] . With an established role in the investigation of intermediate chest pain [49, 50] , its utility as a screening tool in asymptomatic individuals remains contentious. Limited information on the role of CTCA for risk assessment in asymptomatic persons is available. A paucity of clinical trials has resulted in the current American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines not recommending its use in asymptomatic adults (level C evidence) [51] . There is, however, evidence that CTCA can aid in risk stratification of asymptomatic patients via coronary calcium scoring and its role in the screening of asymptomatic high-risk patients is still considered uncertain because of insufficient evidence [52, 53] . Nevertheless, recent evidence has shown that CTCA may be both of clinical benefit and cost effective in the screening of CAD in HIV-positive men [54] .
Independent of traditional cardiovascular risk factors, coronary plaque, especially noncalcified "soft" plaque, is more prevalent and extensive in those with HIV infection compared with their uninfected counterparts (Fig. 3) [11] . The presence of noncalcified plaques on CTCA is associated with greater rates of acute coronary syndrome (ACS) compared with mixed and calcific plaques [55, 56] . Given the predominance of high-risk soft plaque development, there is growing concern that calcium score alone may not adequately assess HIV-infected patients at risk of CAD. Subsequently, CTCA has been considered as the screening tool of choice to rule out obstructive disease in patients who have established risk factors [38] . Nevertheless, to date there are no published trials evaluating the impact of specific therapy on clinical outcomes in patients identified as having noncalcified atheroma by CTCA [51] .
Our approach to the screening of at-risk HIV-infected patients is outlined in Figure 2 . For those with optimal medical management we suggest the use of stress echocardiography to assess for life-threatening plaque. In those with suboptimal medical management or poor metabolic control or in the case of clinician uncertainty regarding management, we advocate the use of CTCA in an effort to assess the burden of disease and dictate the aggressiveness of pharmacological therapy or the need for further intervention.
Clinical outcomes of CAD
ACS is the most relevant clinical manifestation of CAD. ACS encompasses both ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome (NSTEACS), with the latter comprising both non-STEMI and the angina spectrum [57] .
Assessing risk in ACS has been shown to be of clinical importance. In NSTEACS, risk stratification plays a key role in assessing patients and improving outcomes [58] . Similarly, recent studies have suggested that risk assessment may be used to identify those patients who require coronary care unit admission -which has historically been based on criteria for reperfusion therapy rather than absolute risk -and in turn improve both the long-and short-term clinical outcomes of patients with ACS [59] . However, there is concern that those with HIV infection are overlooked in the assessment of risk in ACS, with evidence suggesting that HIV-infected patients are more likely to experience recurrent ACS and restenosis following coronary intervention than their uninfected counterparts [10, 60] .
Currently the presence of HIV infection is not recognized in any ACS risk assessment tools [10] . With the propensity to develop more at-risk plaques and evidence of greater incidence of ACS, there is growing concern that the presence of HIV infection in symptomatic patients is being neglected [60] [61] [62] . Failure to recognize HIV infection as a significant independent risk factor in ACS may be responsible for poorer outcomes in the acute and sub-acute settings. 
Conclusions
There is an increased risk of CAD facing the contemporary HIV-infected population as well as a propensity for these patients to develop high-risk coronary plaques. Moreover, because of a lack of available clinical data, it remains unclear how best to screen and treat this at-risk group. We propose that the use of stress echocardiography and/or CTCA is appropriate in the screening of moderate-to high-risk patients. Future studies should look to identify appropriate screening and risk assessment tools and protocols for the primary and secondary management of this unique population.
